(PROK) ProKidney Corp. Business Model Canvas Research

FDA review and institutional review board oversight are core dependencies for ProKidney Corp., because every trial protocol, consent form, and safety update must clear external scrutiny before and during enrollment. With multiple clinical studies running, these partners shape study design, adverse-event reporting, and the path to future approval.

• FDA drives trial and approval rules
• IRBs protect patients in each study
• Ongoing compliance cuts delay risk

ProKidney Corp. depends on suppliers of reagents, sterile disposables, and collection kits to keep cell-therapy work moving through testing, processing, and shipment of patient-derived material. In clinical-stage cell therapy, even a single lot failure or stockout can stop GMP runs and delay trial dosing.

• Use of sterile consumables is mission-critical
• Supply continuity protects trial timelines
• Quality issues can halt patient material handling

That makes dual sourcing and tight vendor QA a key partnership need for ProKidney Corp.; reliable inputs reduce contamination risk and rework, while shortages can quickly raise costs and push back study milestones.

ProKidney Corp. must file safety data, protocol changes, and results from its 2 pivotal PROACT studies to the FDA and oversight boards on time. Clean reporting keeps the trials authorized and turns each readout into evidence for rilparencel’s path to market.

• 2 pivotal trials to track
• Safety and protocol updates filed fast
• Trial data supports approval and launch

ProKidney Corp. must run clinical supply manufacturing under tight, controlled conditions, with batch-level release testing to keep the cell therapy consistent across sites and patients. Quality systems are central to this work, since the Company is advancing a personalized therapy platform and must prove lot-to-lot comparability, traceability, and GMP compliance for clinical use.

• Controlled GMP manufacturing
• Batch-level quality checks
• Consistency across sites and patients
• Traceability and release control

GMP and quality systems are a core RAC-T resource because cell therapy needs validated, documented release controls to keep batch-to-batch consistency and patient safety tight. ProKidney Corp. has built this around the U.S. cell therapy CMC bar, where lot release, traceability, and deviation control can decide whether a program scales past early clinical work.

• Validated process control
• Release testing and traceability
• Patient-safety protection

ProKidney Corp. is headquartered in Winston-Salem, North Carolina, where it runs development and administration from one core site. That centralized base helps coordinate its clinical programs and corporate functions, as shown in its 2025 SEC reporting and ongoing 2026 operations.

• Winston-Salem, North Carolina base
• Single hub for leadership and admin
• Supports clinical program coordination

ProKidney Corp.'s value is a potential disease-modifying therapy, not just symptom control. Chronic kidney disease affects about 37 million U.S. adults and roughly 1 in 7 adults worldwide, so even slowing progression can delay dialysis and transplant needs.

• Targets progression, not only symptoms
• High value in a 37 million U.S. patient pool
• Could delay dialysis and transplant

ProKidney Corp.'s value proposition is a cell-based renal therapy, not a small molecule, so it stands out in a crowded kidney-care market. That differentiation matters because the company is still in clinical development and its long-term value depends on proving that its cellular approach can slow chronic kidney disease better than standard care.

• Cell therapy, not a pill
• Differentiation in renal care
• Long-term value hinges on data

ProKidney Corp. uses informed-consent support to explain the autologous cell therapy steps, risks, and trial goals in plain language. This matters most in first-in-class studies; ProKidney Corp. stayed pre-revenue in 2025, so clear consent is a key trust tool.

• Plain consent lowers confusion.
• Autologous trials need extra detail.
• Trust matters most in first-in-class.

ProKidney Corp. uses protocol-driven follow-up, so relationships are built around trial visits, lab checks, and predefined milestones, not direct consumer marketing. This creates a tight compliance model where every participant interaction must match the study protocol and safety rules.

• Follow-up is schedule-based and rule-bound.

• Interaction depth is driven by trial compliance.

• Clinical data quality depends on each visit.

Clinical trial registries and study listings give patients, caregivers, and clinicians a clear way to find active studies, and they are a core awareness channel for biotech. For ProKidney Corp., public listings can lift visibility across Phase I, Phase II, and Phase III programs, helping enrollment flow and trial reach.

• Boosts patient and clinician discovery
• Supports Phase I-III enrollment visibility
• Expands low-cost biotech awareness

Medical conferences and peer-reviewed papers are a key credibility channel for ProKidney Corp, a clinical-stage Company. They let the Company share trial data, safety results, and biomarker findings with nephrologists and investors, and they also shape how fast the market expects adoption after Phase 3 readouts and regulatory review.

• Builds specialist trust
• Supports investor diligence
• Sets adoption expectations

Hospitals and specialty clinics are ProKidney Corp.'s core institutional customers because complex cell therapies need controlled delivery, lab support, and close post-treatment monitoring. In 2025, ProKidney remained a clinical-stage company with no product revenue, so adoption depends on treatment centers that can handle advanced procedures and follow-up care.

• Center-based delivery, not retail
• Needs monitoring and lab support
• Key institutional buyers

Payers and healthcare systems are the key buyers if ProKidney Corp.’s RAC-T reaches market, because they will decide reimbursement based on outcomes, cost, and use. In 2025, the Centers for Medicare & Medicaid Services covered about 67 million people in Medicare and about 71 million in Medicaid and CHIP, so access will hinge on how clearly RAC-T lowers hospital use and dialysis-related spend.

Acceptance will likely depend on proof from clinical data and budget impact, since CKD affects about 35.5 million U.S. adults and dialysis can exceed $100,000 per patient per year.

• Reimbursement will drive access.
• Outcomes must beat current care.
• Lower utilization supports coverage.

ProKidney Corp.’s biggest fixed cost here is people: scientists, clinical operations, regulatory staff, and administrators, all run from the Winston-Salem headquarters. In biotech, headcount is a major overhead item, so this cost base stays high before product revenue scales.

• Fixed payroll-heavy cost base
• Winston-Salem HQ supports core staff
• Clinical and regulatory roles dominate

That means cost pressure rises with trial activity and stage of development.

ProKidney Corp. must fund regulatory filings, legal review, and secure trial data systems to keep its clinical program compliant and audit-ready; these controls protect trial integrity and support future FDA approval work. They also sit in non-labor spending, alongside the company’s 2025 R&D and G&A cash use in SEC filings.

• Compliance keeps trials credible.
• Legal work supports approvals.
• Data security adds recurring cost.

ProKidney can turn RAC-T into non-dilutive cash by out-licensing it by region or indication, with deals often pairing upfront fees, milestones, and single-digit to low-teens royalties on future net sales. That matters because ProKidney is still in development and does not yet have product sales, so licensing could fund growth without issuing more shares.

• Out-license RAC-T by region.
• Collect upfront cash and milestones.
• Earn royalties on future sales.
• Reduce dilution risk for investors.

ProKidney Corp. is still pre-commercial, so 2025 product revenue was $0; that makes milestone payments tied to trial progress and research grants key non-dilutive cash sources before launch. These inflows can help fund Phase 2/3 work, but they depend on study hits and partner decisions, so timing is uneven.

• 2025 product revenue: $0
• Milestones track clinical progress
• Grants fund specific studies